Barclays
ABVX

Barclays’s Abivax ABVX Stock Holding History

Barclays’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$653K Sell
4,899
-85,876
-95% -$9.72M ﹤0.01% 3059
2026
Q1 		$10.1M Sell
90,775
-218,014
-71% -$25.8M ﹤0.01% 1447
2025
Q4 		$41.6M Buy
308,789
+232,447
+304% +$25.4M 0.01% 872
2025
Q3 		$6.48M Sell
76,342
-37,049
-33% -$2.27M ﹤0.01% 2002
2025
Q2 		$867K Buy
113,391
+111,913
+7,572% +$729K ﹤0.01% 3436
2025
Q1 		$9.24K Buy
1,478
+383
+35% +$2.59K ﹤0.01% 4877
2024
Q4 		$8.02K Buy
+1,095
New +$10.1K ﹤0.01% 5019

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's ABVX Position: Q2 2026 in Review

Barclays reduced its Abivax (ABVX) stake by 95% in Q2 2026, selling an estimated $9.72M and leaving 4,899 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #3059.

Barclays first reported a position in ABVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $41.6M in Q4 2025. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Barclays held 4,899 shares of Abivax worth $653K as of Q2 2026.
  • Barclays sold 85,876 Abivax shares in Q2 2026, an estimated $9.72M.
  • Abivax made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3059 holding.
  • Barclays first reported a position in Abivax in Q4 2024 and has held it in 7 quarters since.
  • Barclays's Abivax position peaked at $41.6M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.